SCHEMBL7119059

SCHEMBL7119059

C=C(C(=O)O)c1ccc2c(N3CCc4ccc(Cl)cc43)ncnc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 5/20 0.44
CSF1R P07333 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
NOTUM Q6P988 1/20 0.38
CSNK2A1 P68400 1/20 0.38
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
STAT3 P40763 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PDGFRB P09619 1/20 0.36
MKNK1 Q9BUB5 4/20 0.35
MKNK2 Q9HBH9 4/20 0.35
PDCD1 Q15116 2/20 0.35
CD274 Q9NZQ7 2/20 0.35
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
RXRG P48443 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7121718 0.92 EGFR (0.50) EGFRCSF1RNOTUMMKNK1MKNK2
SCHEMBL7118722 0.85 EGFR (0.42) EGFRCSF1RCSNK2A1MKNK1MKNK2
SCHEMBL8650186 0.84 CYP1A2 (0.52) EGFRCSF1RCYP1A2CYP2D6NOTUM
SCHEMBL8646578 0.81 EGFR (0.46) EGFRCSF1RCYP1A2CYP2D6NOTUM
SCHEMBL7119061 0.79 EGFR (0.43) EGFRCSF1RCYP1A2CYP2D6NOTUM
SCHEMBL8651028 0.79 EGFR (0.48) EGFRCSF1RCYP1A2CYP2D6NOTUM
Hydrochloric Acid SCHEMBL8647893 0.79 EGFR (0.47) EGFRCSF1RCYP1A2CYP2D6NOTUM
SCHEMBL27479083 0.78 EGFR (0.50) EGFRCSF1RNOTUMMKNK1MKNK2
SCHEMBL8649559 0.78 EGFR (0.47) EGFRCSF1RCYP1A2CYP2D6NOTUM
SCHEMBL7126863 0.78 EGFR (0.69) EGFRCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030087881-A1 Irreversible inhibitors of tyrosine kinases BRIDGES ALEXANDER JAMES (US) 2003-05-08 US claimed
US-6153617-A Irreversible bicyclic inhibitors of tyrosine kinases WARNER-LAMBERT COMPANY (US) 2000-11-28 US claimed
WO-1999006396-A1 IRREVERSIBLE BICYCLIC INHIBITORS OF TYROSINE KINASES WARNER-LAMBERT COMPANY (US) 1999-02-11 WO claimed
US-20030087881-A1 Irreversible inhibitors of tyrosine kinases BRIDGES ALEXANDER JAMES (US) 2003-05-08 US disclosed
US-6153617-A Irreversible bicyclic inhibitors of tyrosine kinases WARNER-LAMBERT COMPANY (US) 2000-11-28 US disclosed
WO-1999006396-A1 IRREVERSIBLE BICYCLIC INHIBITORS OF TYROSINE KINASES WARNER-LAMBERT COMPANY (US) 1999-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087881-A1 Irreversible inhibitors of tyrosine kinases ERBB2, ERBB3, LCK EGFR 26/4885CSF1R 890/4885CYP1A2 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.